Clinical efficacy of potassium canreonate-canrenone in sinus rhythm restoration among patients with atrial fibrillation - a protocol of a pilot, randomized, double -blind, placebo-controlled study (CANREN-AF trial)

Rafał Dąbrowski, Paweł Syska, Justyna Mączyńska, Michał Farkowski, Stefan Sawicki, Agata Kubaszek-Kornatowska, Piotr Michałek, Ilona Kowalik, Hanna Szwed, Tomasz Hryniewiecki, Rafał Dąbrowski, Paweł Syska, Justyna Mączyńska, Michał Farkowski, Stefan Sawicki, Agata Kubaszek-Kornatowska, Piotr Michałek, Ilona Kowalik, Hanna Szwed, Tomasz Hryniewiecki

Abstract

Background: Atrial fibrillation (AF) is the most frequent cardiac arrhythmia which increases the risk of thromboembolic complications and impairs quality of life. An important part of a therapeutic approach for AF is sinus rhythm restoration. Antiarrhythmic agents used in pharmacological cardioversion have limited efficacy and potential risk of proarrhythmia. Simultaneously, underlying conditions of AF should be treated (e.g. electrolyte imbalance, increased blood pressure, neurohormonal disturbances, atrial volume overload). There is still the need for an effective and safe approach to increase AF cardioversion efficacy. This randomized, double-blind, placebo-controlled, superiority clinical study is performed in patients with AF in order to evaluate the clinical efficacy of intravenous canrenone in sinus rhythm restoration.

Methods: Eighty eligible patients with an episode of AF lasting less than 48 h are randomized in a 1:1 ratio to receive canrenone or placebo. Patients randomized to a treatment intervention are receiving canrenone intravenously at a dose of 200 mg within 2-3 min. Subjects assigned to a control group obtain the same volume of 0.9% saline within the same time. The primary endpoint includes return of sinus rhythm documented in the electrocardiogram within 2 h after drug or placebo administration. Other endpoints and safety outcomes analyses, due to expected lack of statistical power, are exploratory.

Discussion: Current evidence supports renin-angiotensin-aldosterone system (RAAS) inhibition as an upstream therapy in AF management. Excess aldosterone secretion results in proarrhythmic effects. Among the RAAS inhibitors, only canrenone is administered intravenously. Canrenone additionally increases the plasma level of potassium, lowers blood pressure and reduces preload. It has been already used in primary and secondary hyperaldosteronism in the course of chronic liver dysfunction and in heart failure.

Trial registration: ClinicalTrials.gov, NCT03536806. Registered on 25 May 2018.

Keywords: Atrial fibrillation; Canrenone; Cardioversion.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Schedule of enrolment, interventions and assessments. AF atrial fibrillation, ECG electrocardiogram
Fig. 2
Fig. 2
Study procedures and treatment assignment. ECG electrocardiogram, FMC first medical contact, IC informed consent, ME medical examination

References

    1. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016;37(38):2893–2962. doi: 10.1093/eurheartj/ehw210.
    1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071–2104. doi: 10.1161/CIR.0000000000000040.
    1. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001;88:906–909. doi: 10.1016/S0002-9149(01)01905-1.
    1. Wożakowska-Kaplon B, Bartkowiak R, Janiszewska G. A decrease in serum aldosterone level is associated with maintenance of sinus rhythm after successful cardioversion of atrial fibrillation. Pacing Clin Electrophysiol. 2010;33:561–565. doi: 10.1111/j.1540-8159.2009.02673.x.
    1. Soeby-Land C, Dixen U, Therkelsen SK, Kjaer A. Increased plasma aldosterone during atrial fibrillation declines following cardioversion. Cardiology. 2011;118:239–244. doi: 10.1159/000328462.
    1. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention. Europace. 2011;13(3):308–328. doi: 10.1093/europace/eur002.
    1. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. Europace. 2011;13(5):610–625. doi: 10.1093/europace/eur023.
    1. Dabrowski R, Borowiec A, Smolis-Bak E, et al. Effect of combined spironolactone, beta-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study) Am J Cardiol. 2010;106:1609–1614. doi: 10.1016/j.amjcard.2010.07.037.
    1. Neefs J, van den Berg NW, Limpens J, Berger WR, Boekholdt SM, Sanders P, de Groot JR. Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017;231:155–161. doi: 10.1016/j.ijcard.2016.12.029.
    1. Ramsay LE, Shelton JR, Wilkinson D, Tidd MJ. Canrenone—the principal active metabolite of spironolactone? Br J Clin Pharmac. 1976;3:607–612. doi: 10.1111/j.1365-2125.1976.tb04883.x.
    1. Kim KE. Spironolactone. In: Messerli FH. Cardiovascular drug therapy; 2 edition, W.B. Saunders Copmany, Philadelphia, Pennsylvania 19106. 1996. p. 454-60.
    1. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ. Atrial Arrhythmia Conversion Trial Investigators: vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518–1525. doi: 10.1161/CIRCULATIONAHA.107.723866.
    1. Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. Am J Cardiol. 2010;106:1277–1283. doi: 10.1016/j.amjcard.2010.06.054.
    1. Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010;159:1095–1101. doi: 10.1016/j.ahj.2010.02.035.
    1. Fogari R, Mugellini A, Derosa G, Destro M, Zoppi A, Lazzari P. Effect of combined ramipril–canrenone on atrial fibrillation recurrence in hypertensive patients with a history of paroxysmal atrial fibrillation. Circulation. 2014;130(2):A9533.
    1. Bosone D, Costa A, Ghiotto N, Ramusino MC, Zoppi A, D’Angelo A, Fogari R. Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. Arch Med Sci. 2017;13(3):550–557. doi: 10.5114/aoms.2016.62448.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera